Healthcare -
Medical - Diagnostics & Research - OTC - US
$ 0.12
8.9 %
$ 3.37 M
Market Cap
-4.0
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart TTOO
FINANCIALS
Balance Sheet
T2 Biosystems, Inc.
| Current Assets | 25.2 M |
| Cash & Short-Term Investments | 15.7 M |
| Receivables | 1.42 M |
| Other Current Assets | 8.08 M |
| Non-Current Assets | 9.61 M |
| Long-Term Investments | 0 |
| PP&E | 9.05 M |
| Other Non-Current Assets | 555 K |
| Current Liabilities | 56.2 M |
| Accounts Payable | 1.53 M |
| Short-Term Debt | 42.9 M |
| Other Current Liabilities | 11.7 M |
| Non-Current Liabilities | 6.68 M |
| Long-Term Debt | 6.6 M |
| Other Non-Current Liabilities | 83 K |
EFFICIENCY
Earnings Waterfall
T2 Biosystems, Inc.
| Revenue | 7.19 M |
| Cost Of Revenue | 15.4 M |
| Gross Profit | -8.17 M |
| Operating Expenses | 41.5 M |
| Operating Income | -49.7 M |
| Other Expenses | 413 K |
| Net Income | -50.1 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
T2 Biosystems, Inc.
| Net Income | -50.1 M |
| Depreciation & Amortization | 859 K |
| Capital Expenditures | -192 K |
| Stock-Based Compensation | 4.35 M |
| Change in Working Capital | -4.04 M |
| Others | -3.5 M |
| Free Cash Flow | -48.3 M |
Wall Street Analysts Price Targets
T2 Biosystems, Inc.
Wall Street analysts predict an average 1-year price target for TTOO of $5 , with forecasts ranging from
a
low of
$5 to a high of $5 .
TTOO Lowest Price Target
Wall Street Target
5 USD
4066.67%
TTOO Average Price Target
Wall Street Target
5 USD
4066.67%
TTOO Highest Price Target
Wall Street Target
5 USD
4066.67%
4. DIVIDEND
ANALYSIS
TTOO does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
T2 Biosystems, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
133 USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
LEXINGTON, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its multi-year capital equipment supplier agreement with Vizient, Inc., the largest member-driven health care performance improvement company in the United States, has been extended through March 31, 2026. The products covered under the contract with Vizient include the T2Dx® Instrument, the T2Bacteria® Panel and the T2Candida® Panel, which detect sepsis-causing bacterial and fungal pathogens directly from whole blood.
globenewswire.com
- 4 months ago
T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens
Intends to accelerate broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create a new royalty revenue stream Intends to accelerate broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create a new royalty revenue stream
globenewswire.com
- 4 months ago
T2 Biosystems, Inc. (TTOO) Q3 2024 Earnings Call Transcript
T2 Biosystems, Inc. (NASDAQ:TTOO ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Trip Taylor - Investor Relations John Sperzel - Chairman & Chief Executive Officer John Sprague - Chief Financial Officer Conference Call Participants Yi Chen - H.C. Wainwright Operator Greetings.
seekingalpha.com
- 5 months ago
T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the third quarter 2024 and business updates after market close on Thursday, November 14, 2024.
globenewswire.com
- 5 months ago
T2 Biosystems, Inc. (TTOO) Business Update Conference Call Transcript
T2 Biosystems, Inc. (NASDAQ:TTOO ) Business Update Conference Call October 10, 2024 4:30 PM ET Company Participants Trip Taylor - IR John Sperzel - Chairman and CEO Conference Call Participants Eduardo Martinez - H.C. Wainwright Operator Good day, everyone.
seekingalpha.com
- 6 months ago
T2 Biosystems to Host Business Update Call on October 10, 2024
LEXINGTON, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will host a business update call to provide additional details on recent developments after market close at 4:30pm ET on Thursday October 10, 2024. On the call management also plans to address select questions from shareholders that can be submitted in advance to the investor relations team at ir@T2Biosystems.com .
globenewswire.com
- 6 months ago
T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
LEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has entered into a multi-year exclusive U.S. agreement with Cardinal Health (NYSE: CAH),. Under the agreement, Cardinal Health will have exclusive rights to sell T2 Biosystems' FDA-cleared direct-from-blood diagnostics for the rapid detection of sepsis-causing pathogens, including the T2Dx® Instrument, the T2Bacteria® Panel, and the T2Candida® Panel.
globenewswire.com
- 6 months ago
T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union
LEXINGTON, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has successfully defended against an opposition filed against a key patent for its direct-from-whole blood detection method in the European Union.
globenewswire.com
- 7 months ago
T2 Biosystems to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
LEXINGTON, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming H.C. Wainwright 26th Annual Global Investment Conference.
globenewswire.com
- 8 months ago
T2 Biosystems to Attend Upcoming Investor Conferences
LEXINGTON, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in two upcoming investor conferences in August 2024:
globenewswire.com
- 9 months ago
T2 Biosystems, Inc. (TTOO) Q2 2024 Earnings Call Transcript
T2 Biosystems, Inc. (NASDAQ:TTOO ) Q2 2024 Earnings Conference Call July 29, 2024 4:30 PM ET Company Participants Trip Taylor - Investor Relations John Sperzel - Chairman & Chief Executive Officer John Sprague - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Operator Greetings, and welcome to T2 Biosystems, Inc. Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
seekingalpha.com
- 9 months ago
T2 Biosystems Announces Commercial Expansion Through Malaysia and Indonesia Distributor
LEXINGTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of a territory exclusive distribution agreement in Malaysia and Indonesia. Under the terms of the agreement, T2 Biosystems will sell the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance® Panel through the newly appointed distributor.
globenewswire.com
- 9 months ago
8. Profile
Summary
T2 Biosystems, Inc. TTOO
COUNTRY
US
INDUSTRY
Medical - Diagnostics & Research
MARKET CAP
$ 3.37 M
Dividend Yield
0.00%
Description
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Contact
101 Hartwell Avenue, Lexington, MA, 02421
https://www.t2biosystems.com
IPO
Date
Aug. 7, 2014
Employees
113
Officers
Mr. Craig R. Jalbert CIRA
Chief Executive Officer, President, Corporate Treasurer, Corporate Secretary & Director
Dr. Roger Smith Ph.D.
Senior Vice President of Science Research & Development
Ms. Kelley J. Morgan
Chief People Officer
Mr. Brett A. Giffin
Chief Commercial Officer